Meta-analysis of 3 phase 3 RCTs (n=2590) in BCG-naive high-risk NMIBC: checkpoint inhibitor plus BCG maintenance improved event-free survival vs BCG alone (HR 0.77) but not overall survival, with more grade 3+ adverse events.
Meta-analysisn = 2,590
Scilipoti et al. Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials